Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
30 sept. 2021 07h00 HE
|
Trevena Inc.
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average...
Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results
09 mars 2021 07h00 HE
|
Trevena Inc.
-- OLINVYK™ approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H 2021 IND for TRV045 (S1P1 receptor modulator) on track...
Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London
24 août 2020 07h00 HE
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19 The Company expects to report topline data in Q1...
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
02 juin 2020 07h00 HE
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in...
Leading Petroleum Industry Engineer and Researcher Joins Stamper Oil and Gas Technical Advisory Board
19 avr. 2018 03h05 HE
|
Stamper Oil & Gas Corp.
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Stamper Oil & Gas Corp. (TSX-V:STMP) (FSE:TMP2) (OTCQB:STMGF) (“Stamper” or “the Company”), is pleased to announce that Adjunct...
Stamper Announces Appointment of Dr. Qamar M. Malik as the Company's New Technical Consultant
30 août 2017 06h30 HE
|
Stamper Oil & Gas Corp.
VANCOUVER, British Columbia, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stamper Oil & Gas Corp. (TSX-V:STMP) (OTCQB:STMGF) (FSE:TMP2) (“Stamper” or “the Company”), is pleased to announce the appointment...